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Chronic kidney disease is often complicated by uremic
cardiomyopathy that consists of left ventricular hypertrophy
and interstitial fibrosis. It is thought that hypertension and
volume overload are major causes of this disease, but here
we sought to identify additional mechanisms using a mouse
model of chronic renal insufficiency. Mice with a remnant
kidney developed an elevated blood urea nitrogen by 1
week, as expected, and showed progressive cardiac
hypertrophy and fibrosis at 4 and 8 weeks even though their
blood pressures were not elevated nor did they show signs of
volume overload. Cardiac extracellular signal-regulated
kinase (ERK) was activated in the uremic animals at 8 weeks.
There was also an increased phosphorylation of S6 kinase,
which is often mediated by activation of the mammalian
target of rapamycin (mTOR). To test the involvement of this
pathway, we treated these uremic mice with rapamycin and
found that it reduced cardiac hypertrophy. Reduction of
blood pressure, however, by hydralazine had no effect. These
studies suggest that uremic cardiomyopathy is mediated by
activation of a pathway that involves the mTOR pathway.
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Pathological cardiac hypertrophy is associated with a poor
prognosis, the development of cardiac arrhythmias, diastolic
dysfunction, and progression to overt heart failure.1 A similar
condition develops in patients with severe chronic kidney
disease (CKD) that is called uremic cardiomyopathy.1–4 In
this condition, cardiomyocytes enlarge and excess fibrous
tissue is deposited in the heart resulting in the thickening of
the ventricular walls. Uremic cardiomyopathy is associated
with diastolic dysfunction and also, in some cases, with
contractile abnormalities. Nearly 75% of adults have left
ventricular hypertrophy (LVH) at the time of initiation of
dialysis for end-stage renal disease.5 The development of LVH
is an independent risk factor that is associated with reduced
survival in patients receiving dialysis.6
The pathogenesis of uremic cardiomyopathy remains
uncertain. As there is a very high incidence of hypertension
in patients with severe CKD, one hypothesis is that cardiac
hypertrophy develops as a result of pressure overload.
However, correction of hypertension in rats with renal injury
does not prevent the development of cardiac hypertrophy.7
Furthermore, Ayus et al.8 showed that ventricular wall
dimensions were reduced in patients’ receiving intensive
daily dialysis for 1 year when compared with those receiving
dialysis three times per week, despite similar systolic blood
pressures in both groups.
Volume overload may also contribute to LVH by
increasing LV end-diastolic pressure.1,9 A reduction in
intradialytic weight correlates with a reduction in LV mass
index, but LVH may persist after normalization of wall
stress.9 Anemia is frequently present in patients with CKD
and is another factor implicated in the pathogenesis of
uremic cardiomyopathy.1,10 An additional possibility is that
the accumulation of hypertrophic ligands associated with
renal insufficiency or end-stage renal disease may initiate a
signal transduction cascade independent of mechanical stress.
A variety of other substances accumulate in end-stage renal
disease that may modulate cardiac growth and function,
including endothelin-1, parathyroid hormone, tumor necro-
sis factor-a, leptin, interleukin-1a, and interleukin-6.11
The molecular pathways responsible for cardiac hyper-
trophy are dependent on their initiating stimuli. In the
setting of load-induced hypertrophy, mechanical stress can be
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translated through a detection mechanism that is hypothe-
sized to be based on integrins that initiate intracellular
signaling in response to stretch of the extracellular matrix.12
Stretch may also promote the local release of ligands such as
angiotensin II and endothelin-1 that bind to cognate
receptors on the surface of cardiomyocytes to stimulate
intracellular signaling pathways.13,14 Subsequent activation of
the mammalian target of rapamycin (mTOR) complex
activates the ribosomal S6 kinase that promotes mRNA
translation.15 It is hypothesized that uremic cardiomyopathy
may occur through a separate mechanism that is initiated by
activation of Na/K ATPase channels. Cardiotonic steroids
accumulate in patients with CKD and they interact with the a
subunit of transmembrane Na/K ATPases to promote the
activation of the intracellular mitogen-activated protein
kinase pathway.16,17
Rapamycin, a direct inhibitor of mTOR reverses hyper-
trophy due to chronic pressure overload but has not been
investigated in CKD.18 mTOR acts through several down-
stream effectors, including S6 Kinase, 4E-BP, and EF1a, that
all modulate ribosomal function. The PI3 kinase-Akt1
pathway and the extracellular signal-regulated kinase (ERK)
pathway both act upstream of mTOR to promote increased
protein synthesis.19 In this work, we established a murine
model of pressure-controlled uremic cardiomyopathy and
identified mTOR as a key protein in the development of this
condition.
RESULTS
Surgically induced renal injury in mice
To determine whether CKD in mice results in the develop-
ment of cardiac hypertrophy, we studied the effect of
surgically induced renal injury (SIRI) on 12-week-old 129/
SvJ mice. In this method, the right kidney was injured by
cauterization, and a left nephrectomy was performed after 2
weeks. The surgery was well tolerated by wild type 129/SvJ
mice and no mortality was observed.
The metabolic status of mice was determined both 4 and 8
weeks after the completion of SIRI or sham surgery (Table 1).
The serum creatinine was significantly increased in SIRI mice
compared with sham animals at both 4- and 8-week time
points. Four weeks after surgery, the serum creatinine was
0.71±0.006 in sham animals but was increased to
0.133±0.015 in SIRI mice (P¼ 0.003; Table 1). Eight weeks
after surgery, the serum creatinine was 0.104±0.007 in sham
mice but was increased 30.7% to 0.136±0.018 in SIRI mice
(P¼ 0.016). Similarly, the BUN was significantly increased in
SIRI mice at both the 4- and 8-week time points (Table 1).
Four weeks after surgery, the serum BUN was 16.0±4.1 mg/
100 ml in sham mice but was increased to 54.0±4 mg/dl in
SIRI animals (P¼ 0.00003). Eight weeks after surgery, the
serum BUN was 22±1 mg/100 ml in sham mice but was
increased to 83±3 mg/dl in SIRI animals (P¼ 0.0001). A
three- to four-fold increase in urine output was noted in SIRI
animals compared with sham-operated animals at both 4 and
8 weeks after surgery (Table 1). Serum aldosterone levels were
significantly increased in SIRI mice compared with sham
mice at both the 4- and 8-week time points (P¼ 0.042), and
this was associated with significantly elevated urine sodium
loss (P¼ 0.041). Serum angiotensin II levels were transiently
elevated in SIRI mice compared with sham mice 4 weeks after
surgery (P¼ 0.013) but were significantly reduced in SIRI
mice compared with sham mice at the 8-week time point
(P¼ 0.0001; Table 1).20,21 Serum potassium was significantly
decreased in SIRI mice to 3.9±0.1 mmol/l, compared with
4.7±0.2 mmol/l in sham-operated mice (P¼ 0.01; Table 1).
The body weight did not change after surgery and was
25.1±0.6 g in SIRI mice compared with 24.7±0.9 g in sham
animals at the 8-week time point (P¼ 0.51; Table 2).
Interestingly, SIRI mice ate 42.5% more food than sham-
operated animals (Table 2). Despite their increased food
intake, SIRI mice had similar body composition to sham-
operated mice. Measurement of muscle and fat mass by MRI
demonstrated that the lean body mass of SIRI mice was
19.2±1.2 g 8 weeks after surgery and was 20.3±0.8 g in
sham-operated mice (P¼ 0.47; Table 2). Finally, the extra-
cellular fluid volume was nearly identical in SIRI and sham-
operated mice 8 weeks after surgery (Table 2).
Development of cardiac hypertrophy after SIRI
To evaluate the development of cardiac hypertrophy after
SIRI, sequential transthoracic echocardiography was
Table 1 | Metabolic analysis of mice after renal injury
Sham (n=7)
4 weeks
SIRI (n=8)
4 weeks
Sham (n=7)
8 weeks
SIRI (n=8)
8 weeks
SIRI+V (n=7)
8 weeks
SIRI+Rap (n=7)
8 weeks
Ser. creatinine (mg/100 ml) 0.071±0.006 0.133±0.015* 0.104±0.007 0.136±0.018* 0.141±0.008* 0.175±0.022*
Ser. hemoglobin (g/100 ml) 17±0.3 16±0.1 15±1.6 15±1.1 16±0.7 12±2.0*
BUN (mg/dl) 16±4 54±4* 22±1 83±3* 84±6* 108±11*
24 h urine volume (ml) 0.530±90 1.730±190* 1.110±60 3.420±180* 3.640±840* 6.422±930*
Urine [Na+] (mmol/l) 151±13 99±6.3* 162±19 108±8.5 58±4.2* 48±1.5*
24 h urine Na+ (mmol) 0.0800±0.02 0.173±0.05* 0.180±0.01 0.369±0.02* 0.211±0.02* 0.306±0.01*
Ser. potassium (mmol/l) 4.7±0.2 3.9±0.1* 3.8±0.9* 4.2±1.0
Ser. aldosterone (pmol/l) 2454±196 3328±266* 2745±220 3408±273* 3631±290* 3663±293*
Ser. angiotensin II (pg/ml) 34.3±4 142±17* 128±15 97.3±12* 189±23 42.3±5*
Metabolic analysis of 20-week-old mice after sham surgery (Sham), surgically induced renal injury (SIRI), SIRI with daily injections of vehicle (SIRI+V), or SIRI with daily injections
of rapamcyin (SIRI+Rap). Daily injections of vehicle or rapamycin were initiated 4 weeks after SIRI and were given for 4 weeks.
*Po0.05 vs sham-operated mice at the same time point.
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performed on unanesthetized mice 4 and 8 weeks after SIRI
or sham surgery. LV systolic function, measured as fractional
shortening, was nearly identical in SIRI and sham-operated
mice at both time points (Table 3). The echocardio-
graphically determined LV mass index increased from
3.22±0.08 mg/g in sham-operated animals to
3.78±0.14 mg/g in SIRI animals 4 weeks after surgery was
completed (P¼ 0.003). Similarly, at 8 weeks after surgery, the
LV mass index increased from 3.20±0.15 mg/g in sham-
operated animals to 3.96±0.11 mg/g in SIRI animals
(P¼ 0.001).
To confirm whether SIRI promoted cardiac hypertrophy,
we weighed heart tissue of SIRI and control mice 8 weeks
after surgery (Table 4). The biventricular weight-to-tibial
length ratio was increased from 6.3±0.1 mg/mm in sham-
operated mice to 7.4±0.3 mg/mm in SIRI animals
(P¼ 0.012). Furthermore, the LV weight-to-tibial length
ratio increased from 5.0±0.18 mg/mm sham mice compared
with 5.9±0.22 mg/mm in SIRI mice (P¼ 0.006; Table 4).
To evaluate whether SIRI promoted the growth of
individual cardiomyocytes and the deposition of extracellular
matrix in cardiac tissue, we completed a histologic analysis of
ventricular tissue sections. Cardiomyocyte area increased by
119% in SIRI mice when compared with sham-operated
animals 8 weeks after surgery (P¼ 0.0001; Figure 1).
Furthermore, cardiac fibrosis, evaluated in Masson’s
trichrome-stained ventricular sections, increased by 120%
in SIRI mice 8 weeks after surgery (P¼ 0.0001; Figure 2).
To better evaluate cardiac systolic and diastolic function,
we performed cardiac catheterization on anesthetized SIRI
Table 2 | Body mass components of mice after renal injury
Sham (n=7) 8 weeks SIRI (n=8) 8 weeks SIRI+V (n=7) 8 weeks SIRI+Rap (n=7) 8 weeks
Body weight (g) 24.7±0.85 25.1±0.6 26.1±0.5 25.7±0.6
24 h calorie intake (kcal) 14.1±0.75 20.1±1.5* 14.1±1.0 20.4±1.3*
24 h water intake (ml) 1.130±186 3.599±757* 3.630±510* 6.333±646*
24 h urine volume (ml) 1.110±60 3.420±180* 3.640±840* 6.422±930*
Lean body mass (g) 20.3±0.8 19.2±1.2 20.3±1.4 19.9±1.3
Fat body mass (g) 4.1±0.3 3.9±0.2 4.4±0.2 4.3±0.2
Extracellular fluid volume (ml) 4.13±1.24 4.10±0.89 4.21±0.99 4.02±1.16
Lung weight/BW (mg/g) 6.45±0.9 6.21±0.9 6.27±0.0.5 6.59±0.6
Liver weight/BW (mg/g) 26.12±2.4 26.82±2.0 27.06±4.4 26.55±1.9
Spleen weight/BW (mg/g) 2.52±0.3 2.71±0.4 2.93±0.3 2.62±0.4
Metabolic analysis of 20-week-old mice after sham surgery (Sham), surgically induced renal injury (SIRI), SIRI with daily injections of vehicle (SIRI+V), or SIRI with daily injections
of rapamcyin (SIRI+Rap).
*Po0.05 vs sham-operated mice at the same time point.
Table 3 | Echocardiographic analysis of mice after renal injury
Sham (n=12)
4 weeks
SIRI (n=15)
4 weeks
Sham (n=7)
8 weeks
SIRI (n=8)
8 weeks
SIRI+V (n=7)
8 weeks
SIRI+Rap (n=7)
8 weeks
HR (bpm) 613±58 618±31 629±12 637±9 599±12 616±15
PWd (mm) 0.76±0.06 0.89±0.09* 0.76±0.02 0.92±0.02* 0.85±0.05* 0.78±0.02w
IVSd (mm) 0.83±0.02 0.94±0.03* 0.84±0.02 1.03±0.03* 0.90±0.03 0.89±0.04w
LVEDD (mm) 3.3±0.08 3.2±0.06 3.4±0.09 3.2±0.06 3.2±0.07 3.0±0.04
LVM (mg) 84±2.8 99±4.2* 88±3.7 106±2.2* 94±4.9 76.1±3.9w
LVMI (mg/g) 3.22±0.08 3.78±.14* 3.20±0.15 3.96±0.11* 3.63±0.17* 2.94±0.18w
FS (%) 63±1.0 62±1.2 64±1.0 65±0.9 65±1.4 65±1.9
HR, heart rate; PWd, left ventricular posterior wall thickness in diastole; IVSd, interventricular septal wall thickness in diastole; LVEDD, left ventricular end-diastolic diameter;
LVM, calculated LV mass (mg); LVMI, left ventricular mass index (LVM/body weight) mg/g; FS, fractional shortening of the left ventricle in systole.
Transthoracic echcardiographic analysis of mice 4 or 8 weeks after sham surgery (Sham), subtotal nephrectomy (SIRI), SIRI with daily injections of vehicle (SIRI+V), or SIRI with
daily injections of rapamcyin (SIRI+Rap). Daily injections of vehicle or rapamycin were initiated 4 weeks after SIRI and were given for 4 weeks.
*Po0.05 for all comparisons vs sham-operated mice at the same time point except LVMI, where Po0.021; wPo0.05 for all comparisons vs SIRI mice injected with vehicle at
the same time point except LVMI, where Po0.021.
Table 4 | Heart weights of mice after renal injury
Sham
(n=7)
SIRI
(n=8)
SIRI+V
(n=7)
SIRI+Rap
(n=7)
BW (g) 24.7±1.4 25.4±1.1 26.1±0.9 25.7±1.3
BVW (mg) 123±2.7 149±6.5* 138±4.1 114±3.9w
LV (mg) 96.5±3.2 119±4.9* 113±3.4 90.2±3.9w
RV (mg) 25.8±1.7 31.0±1.0* 29.8±2.8 23.7±0.9w
Tibia (TL) (cm) 1.94±0.02 1.99±0.02 2.02±0.02 1.98±0.02
BVW/BW (mg/g) 4.98±0.2 5.9±0.2* 5.3±0.1 4.4±0.1w
BVW/TL (mg/mm) 6.3±0.1 7.4±0.3* 6.8±0.2 5.8±0.2w
LV/BW (mg/g) 3.9±0.1 4.7±0.2* 4.3±0.1 3.8±0.3w
LV/TL (mg/mm) 5.0±0.2 5.9±0.2* 5.6±0.2 4.6±0.2w
RV/BW (mg/g) 1.2±0.0 1.2±0.0 0.9±0.1 1.0±0.1
RV/TL (mg/mm) 1.5±0.1 1.5±0.2 1.3±0.1 1.2±0.1
BW, body weight; BVW, biventricular weight; LV, left ventricular weight; RV, right
ventricular weight; Tibia, tibial length; BVW/BW, biventricular weight-to-body weight
ratio; BVW/TL, biventricular weight-to-tibial length ratio; LV/BW, left ventricular
weight-to-body weight ratio; LV/TL, left ventricular weight-to-tibial length ratio; RV/
BW, right ventricular weight-to-body weight ratio; RV/TL, right ventricular weight-to-
tibial length ratio.
Morphometric analysis of 20-week-old mice 8 weeks after sham surgery (Sham),
subtotal nephrectomy (SIRI), SIRI with daily injections of vehicle (SIRI+V), or SIRI with
daily injections of rapamcyin (SIRI+Rap). Daily injections of vehicle or rapamycin
were initiated 4 weeks after SIRI and were given for 4 weeks.
*Po0.025 vs sham-operated mice; wPo0.021 vs SIRI mice injected with vehicle.
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and control mice 8 weeks after surgery was completed. These
studies demonstrated that LV systolic function, measured by
determining þ dP/dTmax, was unchanged in SIRI mice
(8844±667 mm Hg/s) when compared with sham-operated
mice (8758±856 mm Hg/s) 8 weeks after surgery (Table 5).
Furthermore, diastolic function, measured as t (Glantz), was
similar in both SIRI and sham-operated mice 8 weeks after
surgery. Systolic blood pressure, measured by determining
the peak LV systolic pressure, was 139±11 mm Hg in sham-
operated mice and was similar at 141±12 mm Hg in SIRI
mice (P¼NS). Furthermore, SIRI mice were found to be
normotensive by tail cuff blood pressure measurements and
also by determination of carotid artery pressures with a
Millar catheter (Table 5).
To determine whether a reduction in blood pressure
would affect the development of cardiac hypertrophy after
SIRI, mice were administered the arterial vasodilator
hydralazine. Mice were administered hydralazine in their
drinking water for 8 weeks after the completion of surgery to
deliver a daily dose of 0.001 mg/g. Systolic blood pressure,
determined by cardiac catheterization (LVPmax), was
significantly lower in hydralazine-treated SIRI animals
(101±11 mm Hg) when compared with untreated SIRI
animals (141±12 mm Hg; P¼ 0.037) or untreated sham-
operated animals (139±11 mm Hg; P¼ 0.032; Table 6).
However, the development of cardiac hypertrophy in SIRI
mice was unaffected by hydralazine administration. Indeed,
the LV weight-to-tibial length ratio was 5.8±0.15 mg/mm in
Sham SIRI SIRI + V SIRI + R
1
0.8
0.6
0.4
0.2
0
Pi
xe
l a
re
a/
m
yo
cy
te
∗
∗
Figure 1 | Determination of cardiomyocyte area in ventricular
tissue obtained 8 weeks after surgery. Ventricular tissue was
fixed, embedded, sectioned at 4-micron intervals, stained with
hemotoxylin and eosin, and examined by light microscopy. Scale
bar¼ 20mm. (a) Ventricular section from sham-operated mouse.
(b) Ventricular tissue section from surgically induced renal injury
(SIRI) mouse. (c) Section from SIRI mouse treated with vehicle (V)
for 4 weeks. (d) Section from SIRI mouse treated with rapamycin
(R) for 4 weeks. (e) Quantitative evaluation of cardiomyocyte area
by computerized analysis of ventricular tissue sections. Three high
power fields (400 ) from each of the 4 animals per group were
analyzed by computerized photomicrography with ImageJ v1.24
software. Cardiomyocyte area was calculated by use of the ImageJ
Particle Analyzer algorithm. *Po0.05 vs sham.
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Figure 2 | Evaluation of cardiac fibrosis in ventricular tissue
obtained 8 weeks after surgery. Ventricular tissue was fixed,
embedded, sectioned at 4-micron intervals, stained with Masson’s
trichrome, and examined by light microscopy. (a) Ventricular
section from sham-operated mouse. (b) Ventricular tissue section
from surgically induced renal injury (SIRI) mouse. (c) Section from
SIRI mouse treated with vehicle (V) for 4 weeks. (d) Section from
SIRI mouse treated with rapamycin (R) for 4 weeks. (e)
Quantitative evaluation of fibrotic area/total area by
computerized analysis of ventricular tissue sections. Three
selected high power fields (400 ) from each of the 4 animals per
group were analyzed by computerized photomicrography with
ImageJ v1.24 software. Fibrotic area was calculated by use of the
ImageJ Particle Analyzer algorithm. *Po0.05 vs sham.
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hydralazine-treated SIRI mice, compared with 5.0±0.2 mg/
mm in untreated sham-operated mice (P¼ 0.004; Table 6).
Cardiac molecular adaptations in response to SIRI
To evaluate whether the LVH observed in SIRI mice was
associated with changes in cardiac gene expression, the
expression of marker genes was evaluated by real-time
quantitative polymerase chain reaction (PCR).22,23 The
concentration of mRNAs encoding atrial natriuretic factor
and b-myosin heavy chain in cardiac tissue correlate with the
degree of pathological hypertrophy.22,23 The concentration of
atrial natriuretic factor mRNA was increased by 94% in LV
tissue obtained from SIRI mice 2 weeks after surgery
(P¼ 0.012; Figure 3). The LV concentration of b-myosin
heavy chain mRNA increased by 209% 2 weeks after surgery
(P¼ 0.001). The mRNA levels of both genes returned to
baseline 8 weeks after surgery (Figure 3).
To determine whether SIRI modulates the activation of
intracellular signaling cascades in cardiac tissue, we obtained
ventricular lysates 8 weeks after SIRI or sham surgery.
Immunoblot analysis of ventricular lysates with phospho-
specific antibodies was performed to evaluate the phosphor-
ylation status of ERK1/2, ribosomal S6 protein, and 4E-BP1
(Figure 4). The phosphorylation of ribosomal S6 protein and
4E-BP1 are markers of mTOR activation.16 These experi-
ments demonstrated that ERK1 and ERK2 activation was
significantly increased in SIRI ventricular tissue 8 weeks after
surgery (P¼ 0.011 for ERK1, P¼ 0.007 for ERK2). Further-
more, S6 protein and a subfraction of 4E-BP1 (4E-BP1.2)
phosphorylation were increased 8 weeks after surgery in SIRI
mice (P¼ 0.002 for S6 protein, P¼ 0.016 for 4E-BP1.2).
Rapamycin treatment of SIRI mice
SIRI resulted in the development of cardiac hypertrophy and
was associated with the increased activation of ERK and the
increased phosphorylation of ribosomal S6 protein and
4E-BP1. The increased phosphorylation of ribosomal S6
protein and 4E-BP1 in SIRI cardiac tissue suggested that
mTOR was activated. To evaluate the requirement for mTOR
in the development of cardiac hypertrophy in SIRI mice, mice
were treated with rapamycin (sirolimus) or vehicle by daily
intraperitoneal administration beginning 4 weeks after
surgery. In previous work, rapamycin therapy blocked
pressure overload-induced cardiac hypertrophy in mice.18
Rapamycin was tolerated by SIRI mice and no mortality
was observed. Renal function deteriorated with the admin-
istration of rapamycin, but animals did not become anorexic
and body weight was maintained (Table 1). Treated animals
Table 5 | Invasive hemodynamic analysis of mice after renal
injury and rapamycin treatment
Sham
(n=7)
SIRI
(n=8)
SIRI+V
(n=7)
SIRI+R
(n=7)
HR (bpm) 457±12 453±10 439±12 439±11
LVPmax (mm Hg) 139±11 141±12 132±12 125±9
LVEDP (mm Hg) 5.3±1.5 5.5±0.8 4.3±0.71 3.6±0.9
Tau (Glantz) 11.8±0.4 12.5±1.5 12.0±0.8 14.2±1.4
+dP/dtmax (mm Hg/s) 8758±856 8752±693 8971±100 7624±956
Systolic TCP (mm Hg) 129±4 123±5 124±4 127±2
Diastolic TCP (mm Hg) 82±3 75±4 71±3 73±4
Systolic CAP (mm Hg) 133±11 134±10 138±15 144±14
HR, heart rate obtained during cardiac catheterization; LVPmax, peak systolic LV
pressure; LVEDP, left ventricular end-diastolic pressure; Tau, time constant of
isovolumic change; +dP/dtmax, the maximal change in LV pressure per unit time;
TCP, tail cuff pressure; CAP, carotid artery pressure.
Invasive hemodynamic analysis of 20-week-old mice 8 weeks after sham surgery
(Sham), subtotal nephrectomy (SIRI), subtotal nephrectomyþ vehicle (SIRIþV), or
subtotal nephrectomyþ rapamycin (SIRþ R) by cardiac catheterization.
Table 6 | Analysis of mice treated with hydralazine after renal
injury
Sham (n=7) SIRI+H (n=7) SIRI+H/Sham
BW (g) 24.7±1.4 24.9±0.7 1.01
BVW (mg) 123±2.7 139±2.8 1.13*
LV (mg) 96.5±3.2 115±2.8 1.20*
Tibia (TL) (cm) 1.94±0.02 1.99±0.1 1.02
BVW/BW (mg/g) 4.98±0.2 5.6±0.2 1.12*
BVW/TL (mg/mm) 6.3±0.1 7.0±0.15 1.10*
LV/BW (mg/g) 3.9±0.1 4.6±0.12 1.19*
LV/TL (mg/mm) 5.0±0.2 5.8±0.15 1.17*
HR (bpm) 457±12 414±26 0.90
LVPmax (mm Hg) 139±11 101±11 0.73*
LVEDP (mm Hg) 5.3±1.5 6.14±0.76 1.17
Tau (Glantz) 11.8±0.4 12.7±1.0 1.1
BW, body weight; BVW, biventricular weight; LV, left ventricular weight; Tibia, tibial
length; BVW/BW, biventricular weight-to-body weight ratio; BVW/TL, biventricular
weight-to-tibial length ratio; LV/BW, left ventricular weight-to-body weight ratio; LV/
TL, left ventricular weight-to-tibial length ratio; HR, heart rate; LVPmax, peak systolic
LV pressure; LVEDP, left ventricular end-diastolic pressure; Tau, time constant of
isovolumic change.
Morphometric and invasive hemodynamic analysis of 20-week-old mice 8 weeks
after surgically induced renal injury (SIRI) treated with hydralazine for 8 weeks
(SIRI+H). Each value is then compared with sham mice in simple ratio. Seven animals
subject to SIRI were treated with hydralazine for 8 weeks after surgery. Hydralazine
was added to the animals’ drinking water to provide 0.001 mg/g of drug per day.
*Po0.021 vs sham-operated mice.
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Figure 3 | Analysis of cardiac gene expression in ventricular
tissue obtained 2 and 8 weeks after surgically induced renal
injury or sham surgery. Ventricular tissue was homogenized,
RNA was purified, and the expression of the atrial natriuretic
factor (ANF) and b-myosin heavy chain (b-MHC) genes was
analyzed by quantitative real-time RT-PCR. The specific mRNA
levels for Sham (white) vs SIRI (gray) were measured in samples
from 3 or 4 mice for each condition (indicated by the number in
parentheses). *Po0.01 vs sham.
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became more anemic but there was no evidence of cardiac
dysfunction or dilatation. Indeed, trans-thoracic echocardio-
graphy showed that the LV ejection fraction was 65±1.9% in
rapamycin-treated SIRI mice compared with 65±0.9% in
vehicle-treated SIRI mice 8 weeks after surgery (P¼ 0.73;
Table 3). However, echocardiographic evaluation of mice 8
weeks after surgery revealed that rapamycin treatment
blocked the development of cardiac hypertrophy in SIRI
mice (Table 3). Indeed, the calculated LV mass index was
4.04±0.26 mg/g in vehicle-treated SIRI mice but was only
2.94±0.15 mg/g in rapamycin-treated SIRI mice (P¼ 0.012).
Morphological evaluation of mice 8 weeks after surgery
revealed that the biventricular weight-to-tibial length ratio
was 6.8±0.21 mg/g in vehicle-treated SIRI mice but was
decreased by 17.8% to 5.8±0.20 mg/g in rapamycin-treated
animals (P¼ 0.001; Table 4). Similarly, the LV weight-to-
tibial length ratio was 5.6±0.18 mg/g in vehicle-treated SIRI
mice but was reduced to 4.6±0.2 mg/g in rapamycin-treated
animals (P¼ 0.005).
To determine whether rapamycin treatment affected
cardiomyocyte size or cardiac fibrosis, we completed a
histologic analysis of transverse ventricular tissue sections.
Histologic evaluation of cardiomyocyte area showed that
rapamycin treatment of SIRI mice resulted in an 87%
decrease in cardiomyocyte area compared with vehicle
treatment (P¼ 0.001; Figure 1). The deposition of extra-
cellular matrix was evaluated by Masson’s trichrome staining
of ventricular transverse sections. Cardiac fibrosis decreased
by 53% in rapamycin-treated SIRI mice compared with
vehicle treatment (Po0.001; Figures 2). Analysis of ventri-
cular cytosolic lysates revealed that phosphorylation of
ribosomal S6 protein and 4E-BP1 was reduced in SIRI mice
after rapamycin treatment when compared with vehicle
treatment (Po0.001, P¼ 0.008, respectively; Figure 5).
Cardiac ERK1/2 and Akt phosphorylation was unaffected
by rapamycin treatment (Figure 5).
DISCUSSION
Cardiac hypertrophy develops in patients with CKD and
contributes to the morbidity and mortality of this condition.1
Although hypertension and volume overload may play a role
in the development of uremic cardiomyopathy, more recent
studies suggest that the accumulation of hypertrophic factors
in serum, such as cardiotonic steroids, cytokines, growth
factors, or hormones, may play a more central role.1 Previous
work with animal models of uremic cardiomyopathy mainly
focused on experimentation with rats. However, the genetic
manipulation of rats is much more difficult and expensive
than it is in mice. To date, there is one recent study that
describes a mouse model of uremic cardiomyopathy with
associated significant induction of hypertension.24
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Figure 4 | Analysis of signaling protein phosphorylation in
ventricular tissue obtained from surgically induced renal
injury (SIRI) or sham mice. (a) Analysis of cardiac signaling
protein phosphorylation in ventricular tissue obtained 8 weeks
after SIRI (n¼ 5) or sham surgery (n¼ 4). Ventricular tissue was
homogenized, protein lysates generated, and proteins were
separated by SDS-PAGE followed by immunoblotting with
primary antibodies directed against phosphorylated-Akt1/2
(p-Akt), phosphorylated-ERK1/2 (p-ERK1/2), phosphorylated-
ribosomal S6 protein (p-S6), phosphorylated-4E-BP1, and a-actin
as a loading control. (b) Scanned blot densitometry was
performed with Image J (v1.24) software. *Po0.05 vs sham.
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Figure 5 | Analysis of signaling protein phosphorylation in
ventricular tissue obtained from surgically induced renal
injury (SIRI) or sham mice treated with rapamycin or vehicle.
(a) Ventricular tissue obtained 8 weeks after SIRI in animals
treated for 4 weeks with vehicle (Veh, n¼ 5) or rapamycin (Rapa,
n¼ 5). Ventricular tissue was homogenized, protein lysates
generated, and proteins were separated by SDS-PAGE followed by
immunoblotting with primary antibodies. (b) Scanned blot
densitometry was performed with Image J (v1.24) software.
*Po0.05 vs SIRIþ R.
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For this study, a hemodynamically controlled murine
model of uremic cardiomyopathy was established. In the
weeks following SIRI, mice developed uremia and a relatively
mild reduction in glomerular filtration rate. Mice also
developed a cardiomyopathy that consisted of cardiac
hypertrophy, increased cardiomyocyte size, cardiac fibrosis,
and altered cardiac tissue signaling pathway activation.
Cardiac hypertrophy was detected by morphometry and
transthoracic echocardiography. Altered cardiac signal trans-
duction included increased activation of ERK1/2 protein
kinase and increased ribosomal S6 protein and 4E-BP1
phosphorylation. The phosphorylation of S6 protein and
4E-BP1 are signs of increased mTOR activity. Despite
prominent changes in cardiac structure and intracellular
signal transduction, SIRI mice had systolic blood pressure
that was comparable to sham controls as measured by cardiac
catheterization 8 weeks after surgery.
In the murine model system described here, the left kidney
was surgically removed, but a cautery technique was used to
injure the right kidney so that blood flow was maintained in
the remnant kidney. This technique leaves the renal artery
and segmental arteries intact on the right side so that
perturbation of the renin-angiotensin system is minimized.25
Injury by arterial ligation is frequently used in rat renal injury
model systems and may result in more profound hyperten-
sion than the technique that was employed in the current
work. For example, Griffin et al.26 demonstrated that renal
mass reduction by cautery in rats did not alter blood pressure
for 6 weeks after surgery. In the current work, mice subjected
to SIRI did not develop systolic hypertension. Furthermore,
mice treated with hydralazine developed significant cardiac
hypertrophy despite a reduction in systolic blood pressure.
Therefore, the cardiac hypertrophy and fibrosis that
occurs in SIRI mice appears to be independent of systolic
hypertension.
Although the development of cardiac hypertrophy in SIRI
mice was not a consequence of pressure overload, the role of
volume overload in this process must be considered.1
Chronic renal disease is associated with volume overload,
and body weight is one measure of intravascular volume
status. SIRI mice had similar body weights to sham-operated
animals at both 4 and 8 weeks after surgery. Of note is the
fact that SIRI mice had high urine output both 4 and 8 weeks
after surgery.
To determine whether abnormalities in cardiac signaling in
SIRI mice could help guide therapy for uremic cardiomyo-
pathy, we treated animals with the mTOR inhibitor rapamycin.
Previous work from Shioi et al.18 showed that daily
intraperitoneal administration of rapamycin could block the
development of cardiac hypertrophy in mice after aortic
banding. Administration of rapamycin to SIRI mice from week
4 to week 8 after surgery blocked the development of cardiac
hypertrophy and fibrosis. Vehicle had a minor effect on
normalized heart weight. Therefore, mTOR activity is required
for the development of uremic cardiomyopathy in this murine
model system. The relative role of ERK activation in the
pathogenesis of this condition remains uncertain. Furthermore,
the present results do not address the nature of the initiating
factor(s) that culminate in the development of cardiac
hypertrophy, and it is unclear whether cardiotonic steroids,
cytokines, growth factors, or other ligands that accumulate in
CKD are of primary importance.
In conclusion, we established a murine model of normo-
tensive uremic cardiomyopathy that developed in response to
SIRI. Mice developed prominent cardiac hypertrophy with
fibrosis that was associated with increased cardiac activation of
the ERK and mTOR intracellular signal transduction path-
ways. Treatment of SIRI mice with rapamycin blocked the
development of cardiac hypertrophy and fibrosis when
compared with vehicle-treated animals. As organ transplant
recipients with CKD often take rapamycin as an immunomo-
dulatory drug to suppress organ rejection, it may be possible
to determine whether patients on this medication exhibit
reversal of established cardiac hypertrophy.
METHODS
SIRI in mice
All research involving the use of mice were performed in strict
accordance with protocols approved by the Animal Studies
Committee of Washington University School of Medicine. At 12
weeks of age, male 129/SvJ mice were randomized to undergo SIRI
(SIRI; n¼ 31) or sham surgery (n¼ 14). Mice were anesthetized,
and an incision in the right flank was performed followed by
surgical dissection to expose the right kidney. Capsulectomy
preceded unilateral ablation of 60–70% of the cortical surface of
the right kidney by Bovie cauterization.25 After a 2-week recovery
period, a left flank incision was made and left total nephrectomy in
anesthetized mice was performed. Sham procedures involved
abdominal incisions in the same flank locations of approach.
Quantitation of body fluid constituents and body
composition
Serum aldosterone levels were determined by the University of
Michigan Diagnostic Center for Population and Animal Health in
Ann Arbor, Michigan. Serum angiotensin II was measured at the
Medical College of Wisconsin by radioimmunoassay following HPLC
separation of angiotensin I, angiotensin II, and the primary angiotensin
metabolites as previously described by Mattson and colleagues.27
Calorie intake was measured with a metabolic cage apparatus over a 24-
h period. Urine sodium was measured at Advanced Veterinary
Laboratories in St. Louis, Missouri. Serum creatinine was measured
by Stephen Dunn at Thomas Jefferson University, Philadelphia,
Pennsylvania, by use of HPLC with the following modifications: (1)
column was Zorbax 300-SCX, 5 micron, 2.1 150 mm; (2) mobile
phase was 7.5 mM sodium acetate adjusted to pH 4.4 with acetic acid
(total acetate B15 mM) at a flow rate of 0.50 ml/min (isocratic); (3)
column temperature of 401C; and (4) sample injection volume was
3.0ml.28 Lean body mass was measured by EchoMRI 3-in-1 (Echo
Medical Systems, Houston, TX) at 8 weeks after SIRI. Afterward,
extracellular volume was estimated by measuring the volume of
distribution of sucrose using dilutional technique.29–31
Rapamycin administration after SIRI
A separate population of 17 animals subject to SIRI were monitored
for 4 weeks after surgery and subsequently randomized to
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rapamycin (LC Laboratories, Woburn, MA, USA) injection or
vehicle injection. We treated mice with rapamycin beginning 4
weeks after surgery. Those receiving rapamycin were administered
daily subcutaneous abdominal injections of rapamycin (2 mg/kg/
day) in 50% DMSO 50% saline vehicle.18 Seven control animals
were administered daily injections of 75 ml of a DMSO/saline vehicle
by use of the same technique.
Murine echocardiography
Transthoracic echocardiography was performed in mice that were awake
by use of an Acuson Sequoia 256 Echocardiography System equipped
with a 15-MHz (15L8) transducer as described previously (Acuson, A
Siemens Company, Malvern, PA, USA).22,23 The echocardiographer was
blinded in all cases to the experimental status of the mice.
Murine hemodynamic monitoring
Cardiac catheterization was performed on anesthetized mice as
previously described.32,33 In brief, mice were anesthetized with
ketamine and xylazine and a 1.4-French Millar catheter was placed
in the left carotid artery then advanced into the left ventricle.
Cardiac morphometry and histology
Mice were weighed, and hearts and tibiae were isolated. Cardiac
chambers were dissected and washed in 10 mM PBS. Biventricular
and LV weights were obtained. Tissue microtomes were selected to
approximate the maximum coronal diameter of each heart. H&E
and trichrome staining was performed. Myocyte cross-sectional area
was then calculated using 3–5 random high power fields in the
lateroanterior region of 4 different mice per group. This was
performed with an Axioskop microscope (Carl Zeiss, Inc., Jena,
Germany) with ImageJ (version 1.24) software.
Gene expression analysis
Quantitative real-time RT-PCR analysis on RNA extracted from
heart lysates with Trizol reagent (Invitrogen Corp, Carlsbad, CA,
USA) was carried out with the Taqman master mix kit (Applied
Biosystems, Foster City, CA, USA) according to the manufacturer’s
specifications. The measured abundances of atrial natriuretic factor
and b-myosin heavy chain mRNA were normalized to GAPDH in
each sample as an internal loading control.
Protein analysis
Cytosolic protein lysates from cardiac ventricular tissue were
obtained as previously described.22,23
In brief, ventricular tissue was harvested from mice and prepared
for immunoblot analysis. Primary antibodies employed included
murine monoclonal anti-phospho-p42/44 (Thr202/Tyr204), anti-
phospho-Akt (Ser473), anti-phospho-ribosomal s6 (Ser235/236),
anti-phospho- ribosomal 4E binding protein 1 (4E-BP1) (Thr37/46),
and anti-alpha-actin antibody. Filters were extensively washed in
TBS/T and were then incubated with horseradish peroxidase-
conjugated anti-rabbit or anti-mouse secondary antibody (Amer-
sham, a GE Healthcare Company, Pittsburgh, PA, USA). Bands were
visualized by use of the ECL system (Amersham).
Statistical analysis
All statistical analysis was performed with SigmaStat-3.1 (Systat
Software, Inc., San Jose, CA, USA). Statistical relationships were
determined by the Student’s t-test, where significance was achieved
when a population’s mean value was separated from controls by two
or more standard deviations (P¼ 0.05). All P values calculated were
two-sided. Bonferroni correction was used in analysis of echocar-
diographic and morophometric data requiring 2.5 or more standard
deviations from control values (P¼ 0.021).
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